Association of Perfluoroalkyl and Polyfluoroalkyl Substances With Adiposity
Authors: Andres Cardenas, Russ Hauser, Diane R. Gold, Ken P. Kleinman, Marie-France Hivert, Abby F. Fleisch, Pi-I D. Lin, Antonia M. Calafat, Thomas F. Webster, Edward S. Horton, Emily Oken
Journal: JAMA Network Open (2018)

<h3>Importance</h3> Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are ubiquitous synthetic chemicals that are suspected endocrine disruptors. <h3>Objectives</h3> To determine the extent to which PFASs are associated with increases in weight and body size and evaluate whether a lifestyle intervention modifies this association. <h3>Design, Setting, and Participants</h3> This prospective cohort study included 957 individuals who participated in the Diabetes Prevention Program trial, conducted from July 1996 to May 2001, and the Diabetes Prevention Program Outcomes Study, conducted from September 2002 to January 2014. Statistical analysis was conducted from September 1, 2017, to May 25, 2018. <h3>Interventions and Exposures</h3> The initial lifestyle intervention consisted of training in diet, physical activity, and behavior modification, with the major goals of achieving 7% weight loss with subsequent maintenance and a minimum of 150 minutes per week of physical activity. Participants randomized to placebo received standard information about diet and exercise. A total of 6 plasma PFASs were quantified at baseline and 2 years after randomization, means were calculated from baseline and year 2 concentrations, and means were summed to assess total PFAS burden. <h3>Main Outcomes and Measures</h3> Weight, waist circumference, and hip girth were measured at baseline and at scheduled visits. <h3>Results</h3> Of the 957 participants, 625 (65.3%) were women and 731 participants (76.4%) were between 40 and 64 years of age; 481 participants were randomized to the lifestyle intervention and 476 participants were randomized to the placebo arm. The PFAS concentrations were not different by treatment arm and were similar to concentrations reported for the US population in 1999-2000. The association of PFAS and weight change differed by treatment. Each doubling in total PFAS concentration was associated with an increase of 1.80 kg (95% CI, 0.43-3.17 kg;<i>P</i> = .01) from baseline to 9 years after randomization for the placebo group but not the lifestyle intervention group (−0.59 kg; 95% CI, –1.80 to 0.62 kg;<i>P</i> = .34). Similarly, each doubling in PFAS was associated with a 1.03-cm increase in hip girth in the Diabetes Prevention Program trial for the placebo group (95% CI, 0.18-1.88 cm;<i>P</i> = .02) but not the lifestyle intervention group (−0.09 cm; 95% CI, −0.82 to 0.63 cm;<i>P</i> = .80). No associations were observed for changes in mean waist circumference. <h3>Conclusions and Relevance</h3> Among adults at high risk for diabetes, higher plasma PFAS concentration was associated with increases in weight and hip girth over time, but a lifestyle intervention attenuated these associations. Diet and exercise may mitigate the obesogenic effects of environmental chemicals. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT00004992andNCT00038727